ICMR removes Ivermectin, Hydroxychloroquine drugs from Kovid-19 treatment

However, the new guidelines mention the use of remdesivir and tocilizumab in specific circumstances.

Key guidelines that are regularly emphasized include – wearing of masks, physical distancing and hand hygiene.

Suggesting moderate use of other drugs like remdesivir, the guidelines recommend the former to be used within 10 days of symptom onset only in select moderate or severe COVID-19 patients on supplemental oxygen.

As for the use of tocilizumab, the guideline states to use the drug only for severe COVID-19 patients, preferably within 24 to 48 hours of critical illness or ICU admission.

It suggested that people with mild infection should maintain physical distancing, use of masks indoors, strict hand hygiene.

It further states that symptomatic patients may take antipyretic, antitussive and multivitamins and seek immediate medical attention if they experience difficulty in breathing or high-grade fever or severe cough, especially if lasts for more than five years. asked to search.

People with moderate disease with SpO2 levels of 92–96 percent (88–92 percent in patients with chronic obstructive pulmonary disease) can take methylprednisolone injections and anticoagulation medication.

They should work on changes in breathing, hemodynamic instability and oxygen requirement.

As per the guidelines, the use of NIV (helmet or face mask interface, depending on availability) has been suggested in patients with increased oxygen requirement, if the respiratory function is low, for severe infections.

“Consider the use of HFNC in patients with increased oxygen requirements, should prefer intubation in patients with high respiratory function/if NIV is not tolerated and use the traditional ARDSNet protocol for ventilatory management, “It said.

The guidelines also state to divide methylprednisolone injections of 1 to 2 mg into two doses, usually over a period of 5 to 10 days.

It reported that people over 60 years of age, people with heart disease, high blood pressure, coronary artery disease (CAD), diabetes mellitus, chronic lung/kidney/liver disease, cerebrovascular disease, obesity and other immunocompromised conditions may have severe disease or The risk of mortality is high. .